INFLEXION APPOINTS NEW HEAD OF HEALTHCARE

London, 12^th January 2026 - Inflexion, a leading European mid-market private equity firm, is pleased to announce the appointment of John DiGiovanni as Head of Healthcare, further strengthening the firm’s healthcare expertise. John will work closely with Andy Neville, Partner in the Healthcare team and interim head of Healthcare prior to John’s arrival.

John joins Inflexion with nearly two decades of global healthcare private equity experience. He most recently served as Healthcare sector co-leader, member of the Healthcare Investment Committee and Partner at Arsenal Capital Partners, a leading middle-market private equity firm with $10.8bn in AUM. During his tenure, he played a central role in building and leading one of the industry’s most active and successful healthcare investment platforms.

His direct transaction experience spans more than $2.5bn of enterprise value, including board roles across HCIT, technology-enabled healthcare services, and biopharma services.

Prior to Arsenal, John spent a decade at Baird Capital in the US and UK, where he helped shape the firm’s healthcare investment strategy, led cross-border deal sourcing efforts, and executed multiple successful transactions. He began his career in investment banking at Bank of America Merrill Lynch.

Flor Kassai, Managing Partner at Inflexion, said “We are thrilled to welcome John to Inflexion. Healthcare is an important strategic priority for the firm, and his extensive sector knowledge, leadership experience, and outstanding track record of building and scaling healthcare businesses globally make him ideally suited to lead our efforts. John’s appointment reinforces our focus on partnering with ambitious and innovative healthcare companies.”

John DiGiovanni, Partner and Head of Healthcare at Inflexion, said “Inflexion’s reputation is second to none and I am excited to join to lead the healthcare offering and work with the team to back exceptional businesses that are improving quality of care, enhancing clinical outcomes, and driving meaningful efficiency and innovation across the healthcare ecosystem.”

Ambitious businesses can grow faster with the right capital and expertise, with Inflexion’s flexible funding offering minority or majority capital and access to a sizable team to accelerate growth. The Inflexion team has significant experience in supporting the growth of a number of healthcare companies of different sizes, with recent successes such as ELCG and Medivet, and a growing portfolio which includes CNX Therapeutics, Ensera, Proteros, Rosemont Pharmaceuticals, Tierarzt Plus Partner, Upperton Pharma Solutions and Village Vets. All have access to Inflexion’s value acceleration strategies of M&A, digital enhancement, international expansion, commercial effectiveness, sustainability and talent management.